Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. / Gottschalck, Ida B; Jeppesen, Palle B; Holst, Jens Juul; Henriksen, Dennis B.

I: Scandinavian Journal of Gastroenterology, Bind 43, Nr. 8, 08.2008, s. 929-37.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Gottschalck, IB, Jeppesen, PB, Holst, JJ & Henriksen, DB 2008, 'Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract', Scandinavian Journal of Gastroenterology, bind 43, nr. 8, s. 929-37.

APA

Gottschalck, I. B., Jeppesen, P. B., Holst, J. J., & Henriksen, D. B. (2008). Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scandinavian Journal of Gastroenterology, 43(8), 929-37.

Vancouver

Gottschalck IB, Jeppesen PB, Holst JJ, Henriksen DB. Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scandinavian Journal of Gastroenterology. 2008 aug.;43(8):929-37.

Author

Gottschalck, Ida B ; Jeppesen, Palle B ; Holst, Jens Juul ; Henriksen, Dennis B. / Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. I: Scandinavian Journal of Gastroenterology. 2008 ; Bind 43, Nr. 8. s. 929-37.

Bibtex

@article{cc3083fe455541459758fb6112b5dac4,
title = "Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract",
abstract = "OBJECTIVE: Biochemical markers for bone resorption (s-CTX) are reduced by food intake, whereas markers for bone formation seem to be unaffected by meal status. Glucagon-like peptide-2 (GLP-2) is a peptide secreted from endocrine L cells in the intestinal mucosa in relation to food-intake. Subcutaneous GLP-2 treatment has been shown to reduce bone resorption in postmenopausal women. The objective of this study was to investigate the ability of exogenous GLP-2 to reduce bone resorption in patients with jejunostomy or ileostomy and to elucidate whether an intact gastrointestinal tract and the ability to secrete GLP-2 are required for meal-induced inhibition of bone resorption.MATERIAL AND METHODS: Fifteen control subjects, 13 colectomized patients with an ileostomy and 12 colectomized patients with a jejunostomy (remnant small bowel 89 +/- 53 cm) were given: a) a subcutaneous injection of 1600 microg GLP-2, b) placebo and c) 3.8 MJ of a breakfast meal. Blood was sampled for measurements of s-CTX, s-osteocalcin and GLP-2 for 4 h after each intervention.RESULTS: After the GLP-2 injection, only control subjects showed a significant reduction in s-CTX (24% +/- 13%, p = 0.05, 120 min) compared with baseline values. Patients with an ileostomy had a preserved endogenous postprandial GLP-2 secretion, which was absent in patients with a jejunostomy. Consumption of a meal reduced s-CTX in all groups but significantly less so in the jejunostomy group.CONCLUSIONS: Reductions in bone resorption by exogenous GLP-2 require an intact gastrointestinal tract. The decreased meal-induced inhibition of bone resorption in the jejunostomy patients, who lack a GLP-2 response, supports the view that GLP-2 plays a role in postprandial reduction in bone resorption.",
keywords = "Biological Markers, Bone Resorption, Colectomy, Collagen Type I, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Glucagon-Like Peptide 2, Humans, Ileostomy, Injections, Subcutaneous, Male, Middle Aged, Radioimmunoassay, Retrospective Studies, Short Bowel Syndrome, Treatment Outcome",
author = "Gottschalck, {Ida B} and Jeppesen, {Palle B} and Holst, {Jens Juul} and Henriksen, {Dennis B}",
year = "2008",
month = aug,
language = "English",
volume = "43",
pages = "929--37",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Taylor & Francis",
number = "8",

}

RIS

TY - JOUR

T1 - Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract

AU - Gottschalck, Ida B

AU - Jeppesen, Palle B

AU - Holst, Jens Juul

AU - Henriksen, Dennis B

PY - 2008/8

Y1 - 2008/8

N2 - OBJECTIVE: Biochemical markers for bone resorption (s-CTX) are reduced by food intake, whereas markers for bone formation seem to be unaffected by meal status. Glucagon-like peptide-2 (GLP-2) is a peptide secreted from endocrine L cells in the intestinal mucosa in relation to food-intake. Subcutaneous GLP-2 treatment has been shown to reduce bone resorption in postmenopausal women. The objective of this study was to investigate the ability of exogenous GLP-2 to reduce bone resorption in patients with jejunostomy or ileostomy and to elucidate whether an intact gastrointestinal tract and the ability to secrete GLP-2 are required for meal-induced inhibition of bone resorption.MATERIAL AND METHODS: Fifteen control subjects, 13 colectomized patients with an ileostomy and 12 colectomized patients with a jejunostomy (remnant small bowel 89 +/- 53 cm) were given: a) a subcutaneous injection of 1600 microg GLP-2, b) placebo and c) 3.8 MJ of a breakfast meal. Blood was sampled for measurements of s-CTX, s-osteocalcin and GLP-2 for 4 h after each intervention.RESULTS: After the GLP-2 injection, only control subjects showed a significant reduction in s-CTX (24% +/- 13%, p = 0.05, 120 min) compared with baseline values. Patients with an ileostomy had a preserved endogenous postprandial GLP-2 secretion, which was absent in patients with a jejunostomy. Consumption of a meal reduced s-CTX in all groups but significantly less so in the jejunostomy group.CONCLUSIONS: Reductions in bone resorption by exogenous GLP-2 require an intact gastrointestinal tract. The decreased meal-induced inhibition of bone resorption in the jejunostomy patients, who lack a GLP-2 response, supports the view that GLP-2 plays a role in postprandial reduction in bone resorption.

AB - OBJECTIVE: Biochemical markers for bone resorption (s-CTX) are reduced by food intake, whereas markers for bone formation seem to be unaffected by meal status. Glucagon-like peptide-2 (GLP-2) is a peptide secreted from endocrine L cells in the intestinal mucosa in relation to food-intake. Subcutaneous GLP-2 treatment has been shown to reduce bone resorption in postmenopausal women. The objective of this study was to investigate the ability of exogenous GLP-2 to reduce bone resorption in patients with jejunostomy or ileostomy and to elucidate whether an intact gastrointestinal tract and the ability to secrete GLP-2 are required for meal-induced inhibition of bone resorption.MATERIAL AND METHODS: Fifteen control subjects, 13 colectomized patients with an ileostomy and 12 colectomized patients with a jejunostomy (remnant small bowel 89 +/- 53 cm) were given: a) a subcutaneous injection of 1600 microg GLP-2, b) placebo and c) 3.8 MJ of a breakfast meal. Blood was sampled for measurements of s-CTX, s-osteocalcin and GLP-2 for 4 h after each intervention.RESULTS: After the GLP-2 injection, only control subjects showed a significant reduction in s-CTX (24% +/- 13%, p = 0.05, 120 min) compared with baseline values. Patients with an ileostomy had a preserved endogenous postprandial GLP-2 secretion, which was absent in patients with a jejunostomy. Consumption of a meal reduced s-CTX in all groups but significantly less so in the jejunostomy group.CONCLUSIONS: Reductions in bone resorption by exogenous GLP-2 require an intact gastrointestinal tract. The decreased meal-induced inhibition of bone resorption in the jejunostomy patients, who lack a GLP-2 response, supports the view that GLP-2 plays a role in postprandial reduction in bone resorption.

KW - Biological Markers

KW - Bone Resorption

KW - Colectomy

KW - Collagen Type I

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Follow-Up Studies

KW - Glucagon-Like Peptide 2

KW - Humans

KW - Ileostomy

KW - Injections, Subcutaneous

KW - Male

KW - Middle Aged

KW - Radioimmunoassay

KW - Retrospective Studies

KW - Short Bowel Syndrome

KW - Treatment Outcome

M3 - Journal article

C2 - 19086164

VL - 43

SP - 929

EP - 937

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 8

ER -

ID: 132048351